Global Intraoperative Radiation Therapy Device Market Strategic Research Report

The global intraoperative radiation therapy (IORT) device market occupies an increasingly prominent position within the oncology equipment landscape, valued at approximately USD 185 million in 2024. IORT enables clinicians to deliver a concentrated dose of radiation directly to a tumor bed during surgical resection, eliminating the microscopic residual disease that conventional postoperative radiotherapy addresses only after wound healing delays. This precision approach has gained particular traction in breast, colorectal, brain, and soft-tissue sarcoma surgeries, where margin positivity and locoregional recurrence remain persistent clinical challenges. The convergence of rising global cancer incidence—with the World Health Organization projecting over 35 million new cases annually by 2050—and growing institutional preference for treatment consolidation is elevating IORT from a niche intraoperative adjunct to a standard-of-care consideration at leading oncology centers worldwide.

Three specific catalysts are shaping market momentum. First, the proliferating installation of mobile IORT platforms has freed hospitals from the capital and logistical constraints of dedicated shielded operating theaters, materially broadening the addressable customer base to community cancer centers and mid-tier surgical facilities. Second, accumulating Level 1 evidence from the TARGIT-A and ELIOT randomized controlled trials demonstrating non-inferiority of single-fraction IORT versus whole-breast external beam radiation has accelerated reimbursement approvals in Germany, the United Kingdom, and several U.S. states, reducing the coverage uncertainty that historically suppressed adoption. Third, the integration of real-time imaging guidance with IORT platforms—merging intraoperative ultrasound and CT data with dose-delivery systems—is reducing geometric uncertainty and positioning IORT as a credible alternative to fractionated stereotactic approaches. The primary restraint remains reimbursement fragmentation across emerging markets and the absence of harmonized current procedural terminology codes in several Asia-Pacific healthcare systems, limiting penetration outside specialist academic hospitals.

This report provides a comprehensive analysis of the global IORT device market across the 2025–2032 forecast period, with a historical review extending to 2019. Coverage spans device type, application, regional and country-level revenue, competitive dynamics among ten profiled manufacturers, and the regulatory and reimbursement environment shaping purchasing decisions. The report is designed for corporate strategy teams evaluating product pipeline alignment, investment analysts benchmarking growth opportunities in radiation oncology capital equipment, M&A advisors assessing consolidation targets, and procurement managers negotiating multi-year device contracts.